糖用于预防2型糖尿病:STOP-NIDDM随机试验
Jean-Louis Chiasson1, Robert G Josse, Ramon Gomis
1Research Centre, Centre Hospitalier de l'Université de Montréal, Hôtel-Dieu, Department of Medicine, University of Montreal, Quebec, Canada. jean.louis-chiasson@umontreal.ca
Lancet (London, England)
|June 28, 2002
概括
在葡萄糖耐受性受损的患者中,Acarbose显著延迟了2型糖尿病的发展. 这种α-葡萄糖酶抑制剂还促进了恢复到正常的葡萄糖耐受性,提供了新的治疗选择.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 是一个日益严重的全球健康问题.
- 降低葡萄糖耐受性 (IGT) 是T2DM的先驱状态.
研究的目的:
- 评估阿卡尔博斯在预防或延缓IGT向T2DM进展方面的疗效.
主要方法:
- 一个多中心,随机,安慰剂对照试验,涉及IGT患者.
- 参与者每天接受100毫克阿卡尔或安慰剂三次.
- 主要结局是通过年度口服葡萄糖耐受性测试 (OGTT) 评估的糖尿病发展.
主要成果:
- 亚糖显著降低了IGT转化为T2DM (相对危险0.75,p=0.0015).
- 阿卡尔博斯治疗导致IGT恢复到正常葡萄糖耐受性的显著增加 (p<0.0001).
- 阿卡尔的常见副作用包括气胀和腹.
结论:
- 在IGT患者中,阿卡尔对延迟T2DM发病有效.
- 它可以作为糖尿病预防生活方式修改的替代品或辅助.
- 阿卡尔博斯为糖尿病前期的治疗提供了一个潜在的治疗策略.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...


